Today: 22 June 2026
Browse Category

NASDAQ:DFTX 22 June 2026

Definium announced that its Phase 3 Emerge trial for DT120 in major depressive disorder met its primary endpoint, delivering an 8.1-point placebo-adjusted benefit after six weeks. This positive trial result has generated significant investor interest, with DFTX shares poised for a strong opening on the Nasdaq. Ahead of the market open, Public.com quoted the shares at $40.19 at 9:00 a.m. ET.
Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial

Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial

Definium Therapeutics (DFTX) soared 64.2% pre-market to $40.19 after its Phase 3 Emerge trial showed DT120, an LSD-based tablet, achieved an 8.1-point placebo-adjusted benefit in major depressive disorder at week six, surpassing analyst expectations; investors now await results from a second trial and regulatory review, with approval and market access risks still ahead.
22 June 2026
··

Stock Market Today

  • JPMorgan Defends Broadcom Stock Amid Google AI Chip Contract Debate
    June 22, 2026, 1:36 PM EDT. Broadcom shares dipped as JPMorgan defended the chipmaker's role in Google's AI tensor processing unit (TPU) roadmap. JPMorgan analysts disputed reports of delays, emphasizing no cancellations or postponements in the TPU v9 2-nanometer program. Broadcom's AI semiconductor revenue surged 143% year-on-year to $10.8 billion in Q2 and forecasts over 200% growth to $16 billion for Q3, fueled by custom AI accelerators and networking gear. The firm's supply-assurance deal with Google extends through 2031, covering AI racks beyond chips to networking and infrastructure, underscoring a shift to long-term contract economics. Despite customer concentration risks among Google, Meta, Anthropic, and OpenAI, JPMorgan retained an Overweight rating and $580 price target, highlighting scale and financing in Broadcom's AI business as key near-term catalysts.

Latest articles

IBM’s $15 Billion Move Catches Wall Street’s Eye Ahead of the Open

IBM slide puts AI growth bets in focus as Accenture outlook hits techs

22 June 2026
IBM shares fell 1.8% to $244.57 as Accenture’s weaker outlook pressured IT services stocks, intensifying debate over whether AI will boost IBM’s high-margin software revenue enough to offset risks to its lower-margin consulting business; investors now focus on IBM’s July 22 earnings for clarity on software growth, consulting signings, and free cash flow.
SMH ETF flows point to AI chip trade moving away from Nvidia

SMH ETF flows point to AI chip trade moving away from Nvidia

22 June 2026
VanEck Semiconductor ETF (SMH) pulled in $6.93 billion in one-day net flows—nearly a third of the week’s record tech fund inflows—as investors shifted from leveraged Nvidia bets to diversified chip exposure, sending semiconductor stocks higher even as megacap tech fell, highlighting a sharp rotation in the AI trade.
HIVE shares rise after Paraguay AI pilot resets bitcoin miner outlook

HIVE shares rise after Paraguay AI pilot resets bitcoin miner outlook

22 June 2026
HIVE shares soared 20% after Columbia University researchers validated AI training on HIVE’s Paraguay GPUs, signaling potential for older Nvidia chips in global AI workloads; however, $214.7 million in at-the-market stock-sale capacity remains, posing dilution risk as HIVE pivots from bitcoin mining to AI infrastructure.
Go toTop